RayStation selected as treatment planning system for CYCLHAD Hadrontherapy Centre, France.
M2 PHARMA-November 3, 2017-RayStation selected as treatment planning system for CYCLHAD Hadrontherapy Centre, France
(C)2017 M2 COMMUNICATIONS
Medical technology company RaySearch Laboratories AB (STO:RAYB) announced on Thursday, that following a competitive tender process, it has been chosen as the treatment planning system for the CYCLHAD Hadrontherapy Centre, located in Caen, France.
Reportedly, the RayStation purchase includes the modules for pencil beam scanning, adaptive therapy, biology and patient modelling. Financial details were not available.
This centre, which is due to open in 2018, will be France's third clinical proton therapy centre. CYCLHAD will deliver proton therapy treatments through IBA's ProteusOne compact system, with the first patient treatment scheduled to take place in June 2018.
Also, this centre is owned, operated and managed by SAS CYCLHAD, while treatment will be conducted by the medical teams of Centre FranAaAaAeAoo Baclesse, a comprehensive cancer centre located in Caen. A further phase of expansion is planned for the centre, including the installation of the NHa C400 cyclotron system to enable research with carbon ions.
RaySearch Laboratories develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 3, 2017|
|Previous Article:||Constellation Pharmaceuticals names new chief financial officer and senior vice president, corporate development.|
|Next Article:||BrainStorm names Eyal Rubin as CFO.|